Jon Faiz Kayyem, Director at Inhibrx Biosciences, Inc. (INBX), bought 115,098 shares at $17.89 ($2.0M) on 2024-06-05, disclosed to the SEC on 2024-06-07.
Open-market purchase of $2.0M INBX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.23 | 49,284 | $849K | 42.6% |
| 2 | $17.23 | 49,284 | $849K | 42.6% |
| 3 | $17.89 | 8,265 | $148K | 7.4% |
| 4 | $17.89 | 8,265 | $148K | 7.4% |
| Total | $17.32 avg | 115,098 | $2.0M | 100% |
| Filing → |
| INBX | BUY | 2026-09-08 | $568K | — | Filing → |
| INBX | BUY | 2024-11-22 | $1.5M | — | Filing → |
| INBX | BUY | 2024-06-04 | $9.9M | — | Filing → |